Bosentan hydrate

Ro 47-0203
An Antagonist of Endothelin Receptors
    Cat #: B-170
    Alternative Name Ro 47-0203
  • Lyophilized Powder
  • Bioassay Tested
  • Source Synthetic
    MW: 569.63
    Purity: >99% (HPLC)
    Effective concentration 0.1-100 nM.
      • Bosentan hydrate
    Chemical name 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide;hydrate.
    Molecular formula C27H29N5O6S · H2O.
    CAS No.: 157212-55-0.
    PubChem CID 185462
    Activity Bosentan is a dual antagonist of the ET-A and ET-B endothelin receptors, shown to inhibit endothelin-1 radioligand binding to ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively. In vitro, it competitively inhibits aortic contractions induced by endothelin-1 and tracheal contractions induced by Sarafotoxin S6C with pA2 of 7.2 and 6.0, respectively1. Bosentan is orally bioavailable and active in vivo2.
      • Clozel, M. et al. (1994) J. Pharmacol. Exp. Ther270, 228.
      • Iglarz, M. et al. (2014) Life Sci. 118, 333.
    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at +4°C.
    Solubility Soluble in DMSO. Centrifuge all products before use (10000 x g 5 min).
    Storage of solutions Up to three months at -20°C.
      • Bosentan hydrate
        Alomone Labs Bosentan hydrate inhibits ET-A receptor-mediated Ca2+ mobilization in CHO cells.
        Dose-response curve of Bosentan hydrate (#B-170) inhibition of ET-A receptor-mediated, endothelin-1-evoked Ca2+ mobilization. IC50 was determined at 8.18 nM. Cells were loaded with Calcium 6 dye, incubated with Bosentan hydrate, and stimulated with 15 nM endothelin-1 (EC80). Changes in intracellular Ca2+ levels were detected as changes in maximum relative fluorescence (RLU) using FLIPRTETRA™.
    References - Scientific background
      • Bosentan hydrate (Ro 47-0203) is a synthetic nonpeptide compound that acts as an antagonist of endothelin A (ET-A) and endothelin B (ET-B) receptors. Bosentan hydrate is obtained by structural optimization of Ro 46-2005, a less potent ET-A/ET-B antagonist that is orally bioavailable and active in vivo. Bosentan hydrate competitively inhibits the specific binding of radioligand endothelin-1 to ET-A receptors in human smooth muscle cells with Ki value of 4.7 nM, and to ET-B receptors in human placenta with a Ki of 95 nM1. Bosentan may be a useful drug in the management of clinical disorders associated with vasoconstriction1,2.

        ET-A receptors are predominantly detected in peripheral tissues, especially in vascular smooth muscle tissues where they mediate vasoconstriction. They are also expressed in several regions of the brain. ET-B receptors play an important role in regulating renal function and blood pressure and are expressed in sensory nerves. They are mainly present in medium- and large-sized cell bodies of human trigeminal ganglia. The ET-A receptor has high affinity for endothelin-1 and endothelin-2 and relatively low affinity for endothelin-3, while the ET-B receptor has high affinity for all endothelin isopeptides3,4.

    Target Endothelin receptors
    Last update: 25/08/2019

    Bosentan hydrate (#B-170) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use